Leritrelvir Tablets (Brand Name: 乐睿灵®) Receive Regular Approval from NMPA: A Leap from Conditional to Full Market Authorization

2026 ADA Oral Presentation | Raynovent RAY1225 Injection Phase II Study Shines: Up to 21.2% Weight Loss at 24 Weeks

Raynovent Announces Positive Topline Results from Phase 2b Trial of ZSP1601 in Patients with Biopsy-Confirmed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Top-Line Analysis Data Results Obtained for Two Phase III Clinical Trials of Onradivir Granules (Pediatric) and Onradivir Tablets (Adolescent)!

Raynovent and Qilu Pharmaceutical Reach Strategic Cooperation Agreement to Jointly Advance Commercialization of RAY1225 in China Region!